• Home
  • Mutual Funds
  • Nippon India Pharma Fund Growth

Return

  • 1M
  • 3M
  • 6M
  • 1Y
  • 3Y
  • 5Y
This Fund:
Sensex:
BankFD:

Showing Funds Performance since Sep 07, 2020

Fund Overview

Min. investment

SIP ₹100 & Lump. ₹5000

AUM (Fund size)

₹7,898 Cr

Lock In Period

N/A

Expense Ratio

1.82

Benchmark

BSE Healthcare Total Return

Exit Load

1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.

Summary

Latest details for Nippon India Pharma Fund Growth include a ₹507.0446 NAV as of Apr 24,2026 and returns since inception of 82.16%. Minimum investments start at SIP ₹100. The Nippon India Pharma Fund Growth AUM is ₹7,898 Cr, with a lock-in of N/A years, expense ratio of 1.82%, and benchmark BSE Healthcare Total Return. Exit load is - 1% if redeemed or switched out on or before completion of 1 month from the date of allotment of units.Nil, thereafter.. In the growth review for 1M Month/Year, the fund recorded 5.35% returns, against a category average of 2.81% and a category best of 8.04%.

Calculate Returns

You would have got

close_grey_icon
No Data Found
Your Investment Amount
  • 1
  • 2
  • 3
  • 4
  • 5

Growth Review

DurationFund Return(%)Category Average(%)Category Best(%)
1M5.352.818.04
6M-0.591.748.52
1Y2.775.638.78
3Y22.1317.69108.11

Portfolio Analysis

  • Equity: 99.45%
  • Debt: 0.55%
  • Others
As on: 2026-03-31
View allocation % by

1. Sun Pharmaceutical Industries Limited13.92%
2. Lupin Limited8.45%
3. Divi's Laboratories Limited6.41%
4. Dr. Reddy's Laboratories Limited5.96%
5. Cipla Limited5.42%
6. MedPlus Health Services Limited3.86%
7. Ajanta Pharma Limited3.36%
8. Sai Life Sciences Limited3.15%
9. Mankind Pharma Limited2.87%
10. Aurobindo Pharma Limited2.81%
11. IPCA Laboratories Limited2.77%
12. GlaxoSmithKline Pharmaceuticals Limited2.64%
13. Abbott India Limited2.43%
14. Alkem Laboratories Limited2.17%
15. JB Chemicals & Pharmaceuticals Limited2.09%
16. Pfizer Limited1.90%
17. Gland Pharma Limited1.72%
18. Emcure Pharmaceuticals Limited1.51%
19. Sanofi India Limited0.94%
20. Syngene International Limited0.93%
21. Akums Drugs and Pharmaceuticals Limited0.89%
22. Anthem Biosciences Limited0.88%
23. Biocon Limited0.67%
24. AstraZeneca Pharma India Limited0.62%
25. Indoco Remedies Limited0.38%
26. Concord Biotech Limited0.14%

1. Apollo Hospitals Enterprise Limited5.15%
2. Max Healthcare Institute Limited3.24%
3. Vijaya Diagnostic Centre Limited3.15%
4. Dr. Lal Path Labs Limited2.02%
5. Thyrocare Technologies Limited1.94%
6. Narayana Hrudayalaya Limited1.67%
7. Suraksha Diagnostic Limited1.12%
8. Fortis Healthcare Limited1.11%

1. Sanofi Consumer Healthcare India Limited1.16%

About Fund

Nippon India Pharma Fund Growth managed by Nippon India Mutual Fund,is a Healthcare & Pharmascheme with Assets Under Management of ₹7,898 Crore. The fund benchmarks its performance against the BSE Healthcare Total Return while maintaining an expense ratio of 1.82. Under the expert guidance of Sailesh Raj Bhan ,the fund implements a disciplined investment approach aligned with its mandate. The scheme requires a minimum investment of ₹500 for SIP and ₹1,000 for lump sum investments, making it accessible to diverse investor profiles.

Fund Managers

Sailesh Raj Bhan

Mr. Bhan is an MBA with specialization in Finance and CFA. He has over 9 years experience in Equity Securities research and analysis. His pervious experiences include stints with Emkay Share & Stock Broker Pvt. Ltd (2001-2003) where he was Head - Research, Shah & Sequeira Invst. P. Ltd. Analyst (1996-2001), as part of Equity Research, and ICFAI - Securities Research Center (1995- 1996) as an Analyst - Equity Research.

Peer Comparison

Fund NameRatingsAUMExpense Ratio
This FundDSP Healthcare Fund Growth32891.76 CR1.94
This FundTata India Pharma & HealthCare Fund Growth21229.42 CR2.15
This FundNippon India Pharma Fund Growth47898.24 CR1.82
This FundUTI Healthcare Fund Growth31055.53 CR2.28
This FundICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund Growth56293.14 CR1.87
Fund Name1Y3Y
This FundDSP Healthcare Fund Growth0.657877.434
This FundTata India Pharma & HealthCare Fund Growth0.63781.0709
This FundNippon India Pharma Fund Growth2.771182.1575
This FundUTI Healthcare Fund Growth5.390893.2855
This FundICICI Prudential Pharma Healthcare & Diagnostics (P.H.D) Fund Growth4.5249102.8409

FAQs

Nippon India Pharma Fund Growth's fund is managed by experienced SEBI-registered investment fund manager , who implements the fund's strategy through research-backed decisions while adhering to its stated objectives.

The expense ratio of Nippon India Pharma Fund Growth is 1.82. This expense ratio is calculated by dividing the fund's operating expenses by its net assets.

Nippon India Pharma Fund Growth’s fund performance is as follows:
  • 1 Month : 5.35%
  • 6 Months : -0.59%
  • 1 Year : 2.77%
  • 3 Years : 22.13%
Returns of Nippon India Pharma Fund Growth are updated daily based on NAV of ₹ 507.0446 as on Apr 24,2026. Since inception, the return has been 82.16%.

You can invest in Nippon India Pharma Fund Growth through SIP with a minimum of ₹500 monthly or make a lump sum investment of a minimum ₹1,000. Additional purchase minimums vary by scheme.

The fund size (AUM) of Nippon India Pharma Fund Growth is ₹7,898 crore. It changes based on market performance, inflows, and outflows.

You can track your investment in Nippon India Pharma Fund Growth through our website, our Choice FinX mobile app, regular statements, and email updates. Our customer support team is available for queries.
Min Inv Amount: ₹500